Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief Report

Authors:

Abstract
No abstract available
Funding Information
  • Bayer AG
  • AstraZeneca
  • Pfizer Inc
  • Eli Lilly and Company
  • Merck Sharp & Dohme Ltd
  • Roche

This publication has 15 references indexed in Scilit: